The All Wales Medicines Strategy Group (AWMSG) has recommended AbbVie’s Maviret for use within NHS Wales, UK, to treat adults suffering from chronic hepatitis C virus (HCV) infection.

Indicated for HCV infection across all major genotypes (GT1-6), Maviret is a once-daily, ribavirin-free regimen with a combination of 100mg of glecaprevir and 40mg of pibrentasvir, which targets and inhibits proteins required for the viral replication.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Discovered under the firm’s alliance with Enanta Pharmaceuticals, glecaprevir is an inhibitor of NS3/4A, while pibrentasvir inhibits NS5A.

University Hospital of Wales Infectious Diseases & Microbiology consultant Dr Brendan Healy said: “New treatments, such as Maviret, offer patients with all the major genotypes of hepatitis C a chance of clearing the virus with as little as eight weeks of treatment.

“This is good news for patients who now have a number of treatment choices that can benefit their quality of life and health.”

“New treatments, such as Maviret, offer patients with all the major genotypes of hepatitis C a chance of clearing the virus with as little as eight weeks of treatment.”

Healy further added that the cost-effective treatment could make a positive impact on overall public health by minimising the pool of disease and aid the elimination agenda of World Health Organisation (WHO).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Maviret secured marketing authorisation from the European Commission in July this year for the treatment of HCV infection in adult patients without cirrhosis.

The authorisation was supported by results obtained from eight registrational studies carried out under the firm’s clinical development programme in more than 2,300 subjects across 27 countries.

Maviret was reported to have demonstrated a 97% cure rate following eight weeks of treatment.

Image: Hepatitis C virus. Photo: courtesy of BruceBlaus via Wikipedia.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
NorthWest EHealth has won three 2025 Pharmaceutical Technology Excellence Awards for Innovation, Safety and Diversity. Explore how its ConneXon platform is transforming SAE reporting and real-time safety oversight, while FARSITE delivers socio-economically inclusive recruitment to boost trial efficiency, data integrity and regulatory-grade representativeness.

Discover the Impact